Pmv Pharmaceuticals Ownership
| PMVP Stock | USD 1.27 0.01 0.79% |
Shares in Circulation | First Issued 2020-03-31 | Previous Quarter 52 M | Current Value 52 M | Avarage Shares Outstanding 39.2 M | Quarterly Volatility 17.1 M |
Pmv |
Pmv Stock Ownership Analysis
About 81.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 0.37. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Pmv Pharmaceuticals recorded a loss per share of 1.14. The entity had not issued any dividends in recent years. PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Cranbury, New Jersey. Pmv Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 54 people. To find out more about Pmv Pharmaceuticals contact David Mack at 609 642 6670 or learn more at https://www.pmvpharma.com.Besides selling stocks to institutional investors, Pmv Pharmaceuticals also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Pmv Pharmaceuticals' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Pmv Pharmaceuticals' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Pmv Pharmaceuticals Quarterly Liabilities And Stockholders Equity |
|
Roughly 2.0% of Pmv Pharmaceuticals are currently held by insiders. Unlike Pmv Pharmaceuticals' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Pmv Pharmaceuticals' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Pmv Pharmaceuticals' insider trades
Pmv Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Pmv Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Pmv Pharmaceuticals backward and forwards among themselves. Pmv Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Pmv Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Jacobs Levy Equity Management, Inc. | 2024-12-31 | 539.9 K | Stonepine Capital Management Llc | 2024-12-31 | 535.8 K | Citigroup Inc | 2024-12-31 | 514.9 K | Two Sigma Investments Llc | 2024-12-31 | 507 K | Aldebaran Capital Llc | 2024-12-31 | 502.2 K | Peapod Lane Capital Llc | 2024-12-31 | 445.7 K | Geode Capital Management, Llc | 2024-12-31 | 421.7 K | M&t Bank Corp | 2024-12-31 | 399.5 K | Connor Clark & Lunn Inv Mgmt Ltd | 2024-12-31 | 370.9 K | Orbimed Advisors, Llc | 2024-12-31 | 6.5 M | Sio Capital Management, Llc | 2024-12-31 | 3.6 M |
Pmv Pharmaceuticals Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Pmv Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Pmv Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Pmv Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Pmv Pharmaceuticals Outstanding Bonds
Pmv Pharmaceuticals issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Pmv Pharmaceuticals uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Pmv bonds can be classified according to their maturity, which is the date when Pmv Pharmaceuticals has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| US69354NAD84 Corp BondUS69354NAD84 | View | |
| PRAA 8375 01 FEB 28 Corp BondUS69354NAE67 | View | |
| US69351UAW36 Corp BondUS69351UAW36 | View | |
| PPL 525 15 MAY 53 Corp BondUS69351UBB89 | View | |
| PPL 5 15 MAY 33 Corp BondUS69351UBA07 | View | |
| PPL ELEC UTILS Corp BondUS69351UAM53 | View | |
| PPL ELEC UTILS Corp BondUS69351UAU79 | View | |
| PPL ELEC UTILS Corp BondUS69351UAV52 | View |
Additional Tools for Pmv Stock Analysis
When running Pmv Pharmaceuticals' price analysis, check to measure Pmv Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pmv Pharmaceuticals is operating at the current time. Most of Pmv Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Pmv Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pmv Pharmaceuticals' price. Additionally, you may evaluate how the addition of Pmv Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.